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-OHE1) are thought to
curtail the greater oxidative stress found in the development and
progression of disease conditions including atherosclerosis. We




-isoprostane levels, a biomarker of
oxidative stress.
 
Design and participants 
 
Data were obtained from 1647 women,
aged 47–57 years, participating in the fifth annual follow-up of the










concentrations were determined by enzyme-linked immunosorbent













-isoprostane concentrations were elevated in women
who smoked, a behaviour associated with increased oxidative stress,





concentrations among pre- and postmenopausal women who
smoked were 1082 and 1064 pg/ml, respectively, values double those
in pre- (343 pg/ml) and postmenopausal (379 pg/ml) nonsmoking




-isoprostane concentrations were positively



































 = 0·59 in pre-












 = 0·20). Associations were adjusted for age, body mass index





This study does not support the commonly held
hypothesis that levels of endogenous E2 or its oestrone metabolites
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It has been hypothesized that physiological levels of oestradiol (E2)









-OHE1), favourably modulate oxida-
tive stress, potentially attenuating the development and progression




 While the concept
of oestrogens as antioxidants is intriguing and might explain
differential rates or timing of cardiovascular disease between men
and women, the evidence remains controversial.























 have shown that, in postmenopausal women,
oestrogen replacement diminished circulating oxidized LDL levels.
Studies of oxidative stress according to sex difference or menopause
transition to postmenopause are too few in number to clarify the role























-isoprostane levels were about 20% lower, not higher, in men




. reported increased levels













 we examined the potential antioxidant associations
of oestrogens considering stages of menopause. We hypothesized
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-isoprostanes would be similar in pre- and postmenopausal
women using hormone therapy (HT), and dissimilar to the
associations in postmenopausal women without HT use. These
hypotheses were tested while adjusting for lipids, body mass index
(BMI), race/ethnicity, smoking, exercise, vitamin E and iron






Sampling and study population
 
Data were from 1647 enrolees at the fifth annual follow-up visit of
the Study of Women’s Health Across the Nation (SWAN), a com-




Eligible participants were from Boston MA, Chicago IL, the Detroit
area MI, Los Angeles CA, Hudson County NJ, Oakland CA, and
Pittsburgh PA. At baseline, eligibility criteria for the longitudinal
cohort were: age 42–52 years; intact uterus and at least one ovary;
no current use of oestrogens or other medications known to affect
ovarian function; at least one menstrual period in the 3 months
before enrolment; and self-identification as a member of one of the
five eligible racial/ethnic groups. The sites enrolled a Caucasian and
non-Caucasian sample including African-American women in Boston,
Chicago, the Detroit area and Pittsburgh, and Japanese, Chinese
and Hispanic women in Los Angeles, Oakland and New Jersey,
respectively. Two sites, Chicago and Newark, did not collect annual
urine samples from enrolees so the only contribution for these sites
comes from 44 women at the Chicago site who provided urine
samples for a SWAN substudy. There was Institutional Review Board





This study was limited to specimens collected during the fifth annual
follow-up examination and available through the SWAN Repository.
When possible, early morning blood draws occurred in the fasted
state during days 2–5 of the early follicular phase of the menstrual




-isoprostane analyses and oestrone
metabolites were collected on the days of blood draw (usually on
days 2–5 of the early follicular phase and, by protocol, prior to 1100 h).
At the fifth follow-up visit, 96% of samples were acquired fasting,
97% were acquired before 1100 h, and 53% of samples were collected
in days 2–5 of the follicular phase of the menstrual cycle. Assays were
completed in the CLASS laboratory, University of Michigan.
Serum E2 concentrations were measured with a modified, off-line
ACS:180 (E2-6) immunoassay (Bayer Diagnostics Corp., Norwood,
MA). The assay range for E2 was calibrated to address the lower
values associated with the follicular phase or with the postmeno-
pause. Inter- and intra-assay coefficients of variation (CVs) were





-OHE1 were assayed by enzyme immunoassay




 The inter- and intra-assay CVs





-OHE1 are found as 3-glucuronides or 3,3,16-
glucuronides, it was necessary to remove these sugars to achieve
recognition sites for the monoclonal antibodies. Therefore, the
oestrogens were deconjugated from glucuronic acid and sulfate using









. The assay range was 0·6–40·0 ng/ml.





according to the manufacturer’s instructions (Cayman Chemical,
Ann Arbor, MI). Samples were applied to the column, washed with
buffer and eluted with 95% ethanol. Following evaporation of
solvent, the dried samples were diluted 1 : 10 with 0·1 M phosphate




-isoprostane EIA kit (Cayman
Chemical). The standard curve range was 3·9–500 pg/ml. Samples
were read at 405 nm in a 96-well microplate reader. The postextraction




 = 83 pairs) and









 = 1707 pairs).
Lipids were assayed at the Medical Research Laboratories,
Highland Heights, KY, which is certified by the Centers for Disease




 All lipid and
lipoprotein fractions were analysed on ethylenediaminetetraacetic
acid (EDTA)-treated plasma. Total cholesterol and triglycerides
were analysed by enzymatic methods and high density lipoprotein
cholesterol (HDL-C) was isolated using heparin–2 M manganese





 126 mg/dl (measured using a hexokinase-coupled reac-
tion on a Hitachi 747–200; Boehringer Mannheim Diagnostics,
Indianapolis, IN) or self-reported use of insulin or oral medications
for diabetes.
 
Physical and interview-based measures
 
Weight (kg) was measured using a balance beam and electronic
scales; height (m) was measured using stadiometers. The data were
used to calculate BMI (weight in kilograms divided by height
squared in metres).
Women were designated as pre- or perimenopausal unless they
had 12 months of amenorrhoea and then they were designated as
postmenopausal. Because of their limited number, women who had
surgical menopause were excluded from these data analyses. Use of
exogenous hormones (HT) was self-reported.
Data on smoke exposure were obtained from a self-administered









physical activity was based on the frequency, intensity and duration
of the two sports or exercise activities reported by the participant as




 Estimates of usual annual





 administered in four
languages, English, Spanish, Chinese or Japanese. Serving sizes were









 Total alcohol con-
sumption per day was categorized as none, less than half a serving




 15 g). Vitamin and mineral
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Analyses were conducted using SAS version 9·1 software. Informa-
tion was excluded from the baseline enrolment of 3302 women for





 = 696) and unavailable oestrogen metabolite data because the





 = 571). Of the remaining 2035 participants, 42 women had
surgical menopause and 346 did not have repository specimens
available for analyses. The final analytical sample consisted of
371 (23%) African-American, 837 (51%) Caucasian, 202 (12%)
Chinese and 237 (14%) Japanese women.
Median and interquartile ranges (IQRs) were calculated for









-isoprostanes, lipids, BMI and age. All continuous variables except
for age were log-transformed to satisfy the normality assumption in
parametric testing. Analyses of covariance (ANCOVAs) and multiple
variable regression analyses were the primary statistical approaches.
Type III sums of squares were used to estimate the adjusted corre-
lations. Adjusted group means were identified using ANCOVAs and








 < 0·05. Ninety-five per cent confidence intervals (CIs) were used to
describe statistical probabilities of associations with ANCOVA models.
Data were stratified by current smoking behaviour because
smoking behaviour had a strong main effect and interaction with
menopause status. A potential statistical interaction with race could
not be tested because smoking was infrequently reported by Chinese
or Japanese women, making full statistical adjustment or interaction
testing inappropriate. Data were adjusted for age, BMI, race, physical
activity level, and lipids as continuous variables. Adjustment also
included vitamin E supplement use, iron supplement use, and
diabetes as categorical variables. There were no associations with





The overall median age at the fifth annual visit was 51 years, with
premenopausal women slightly younger (50 years) and postmeno-









-isoprostane concentrations were signifi-




 nonsmokers before and





concentrations in smokers were almost double the mean level of
nonsmokers in both African-American and Caucasian women, with
few smokers among Chinese and Japanese women.
Attribute
Pre- and 
perimenopausal Postmenopausal HT users
Age (years) 50·0 (48–51) 53·0 (51–54) 52·0 (50–54)
BMI (kg/m2) 26·5 (23–32) 27·0 (23–32) 26·0 (23–31)
Waist circumference (cm) 84·2 (74–97) 86·3 (74–100) 83·3 (74–96)
Oestradiol (pg/ml) 38·4 (20–79) 13·2 (10–21) 39·5 (22–68)
2-Hydroxyoestrone (pg/ml) 8·7 (5–15) 5·3 (3–9) 17·3 (8–41)
16α-Hydroxyoestrone (pg/ml) 6·1 (4–10) 4·3 (3–6) 9·0 (5–18)
F2a-isoprostanes (pg/ml) 433 (235–785) 413 (231–747) 495 (262–872)
FSH (mIU/ml) 22·5 (12–54) 87·3 (62–116) 46·2 (25–71)
Race
African-American 205 (22·7) 99 (26·2) 66 (18·1)
Caucasian 445 (49·3) 168 (44·4) 223 (61·1)
Chinese 114 (12·7) 54 (14·3) 34 (9·3)
Japanese 138 (15·3) 57 (15·1) 42 (11·5)
Smoking
Current 99 (11·0) 50 (13·2) 37 (10·1)
Not smoking 803 (89·0) 328 (86·8) 328 (89·9)
Exercise
Lowest two quintiles 332 (37·6) 157 (42·9) 134 (37·8)
Middle two quintiles 373 (42·2) 136 (37·2) 144 (40·7)
Highest quintile 179 (20·2) 73 (19·9) 76 (21·5)
Alcohol consumption
More than half a serving/day 163 (18·8) 70 (19·0) 90 (25·1)
Less than half a serving/day 268 (31·0) 94 (25·5) 105 (29·3)
None 434 (50·2) 204 (55·5) 163 (45·6)
Diabetes
Yes 69 (8·2) 42 (11·6) 34 (9·7)
No 767 (91·8) 320 (88·4) 317 (90·3)
Values are given as n (%) or median (interquartile range).
Table 1. Characteristics of 1647 participants at 
the fifth follow-up SWAN examination (excluding 
women with hysterectomy)
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 = 0·09) among women who did not smoke




-isoprostane concentration in women using





0·0002). In nonsmokers, the mean E2 concentrations









 < 0·0001) in postmenopausal women
as compared to premenopausal women (Table 2). The mean 2-





0·0001) than in premenopausal women. Women using HT had




























-isoprostane concentrations for women
who were premenopausal, postmenopausal or using HT were 1082,
1064 and 871 pg/ml, respectively. These values were not statistically
different from each other. In addition, the mean E2 concentration in
premenopausal women smokers was greater than in postmenopausal








 < 0·004). E2 concentrations
in women using HT were somewhat higher than in premenopausal




 = 0·24). Among smokers, mean 2-OHE1 con-
centrations for women who were premenopausal, postmenopausal
or using HT were 12·5, 7·3 and 29·8 pg/ml, respectively. These values





for women smokers who were premenopausal, postmenopausal or
using HT were 8·8, 6·5 and 11·3 pg/ml, respectively, values that were
not statistically significantly different from each other (see Table 2).
 
Associations of oestrogens with isoprostanes
 
As shown in Table 3, among nonsmoking women, E2 concentrations





pausal women or in those who used HT. In postmenopausal women,






 = 0·20 (95% CI 0·08–0·31). This and
all subsequent partial correlations include adjustment for age, BMI,
race, lipids, menopausal status, exercise, alcohol consumption and
diabetes.
In women who did not smoke, consistent, substantial and positive



















































 = 0·59) and






 = 0·46) (see Table 3).




-isoprostane levels were not





levels were positively associated with 2-OHE1 concentrations in







 = 0·28 and 0·55, respectively), as well as in postmenopausal
women (
 
ρY|X = 0·39) after adjustment for covariates. F2a-isoprostane
levels were positively associated with 16α-OHE1 concentrations in
premenopausal women (ρY|X = 0·39), postmenopausal women
(ρY|X = 0·64), and women using HT (ρY|X = 0·58).
The patterns between oestrogens and F2a-isoprostanes were
similar even when data were stratified by race groups or BMI categories
of obesity (data not shown).
Discussion
It has been argued9 that oestrogens might exert antioxidant actions
in modifying F2a-isoprostane production because of the presence of














Oestradiol (pg/ml) 38·9 (2·4) 14·7 (0·9) 36·0 (1·5)  35·7 (4·5)  19·4 (3·2) 46·1 (8·4)
2-Hydroxyoestrone (pg/ml) 7·4 (0·3) 4·9 (0·3) 15·3 (0·9)  12·5 (1·6)  7·3 (1·2) 29·8 (5·5)
16α-Hydroxyoestrone (pg/ml) 5·4 (0·2) 4·1 (0·02) 9·5 (0·05)  8·8 (1·1)  6·5 (1·0) 11·3 (2·0)
F2a-isoprostanes (pg/ml)  343 (12·4)  379 (19·5)  425 (21·9) 1082 (139·6) 1064 (174·1)  871 (159·6)
*Adjusted for age, BMI, race, lipids, menopausal status, exercise, alcohol consumption and diabetes.
Fig. 1 F2a-isoprostane concentrations among premenopausal women, 
postmenopausal women, and hormone therapy (HT) users, by race and 
smoking status at the fifth follow-up SWAN examination.
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an aromatic hydroxyphenol structure.27 However, our data do not
support that hypothesis; indeed, the opposite may be true. Although
there was a statistically significant correlation between endogenous
E2 and F2a-isoprostanes in postmenopausal women, the direction of
the correlation was positive, not negative, and circulating levels of
E2 were low. The same trend was observed with exogenous hormone
use. The correlations of the oestrone metabolites with F2a-isoprostanes
were positive, not negative, and fairly strong. Furthermore, the
strengths of these associations were not diminished following adjust-
ment for race, menopause status, BMI, lipids, smoking behaviour,
vitamin E and iron supplement use, and level of alcohol consumption.
This led us to conclude that higher levels of these oestrone metabolites
were associated with greater oxidative stress and did not support our
a priori hypothesis. However, these three aspects of oestrogen status
do not reflect all oestrogen metabolites and it is possible that a non-
measured analyte may have a different relationship than the very
striking relationships we observed. For example, Tang et al. reported
that 4-hydroyxoestrone was a potent inhibitor of lipid peroxidation
in a cell culture system28 and Seeger et al. reported that 2-
methoxyoestrone and 2-hydroxyoestrone inhibited lipid peroxidation
better than E2 and 16α-OHE1 in pooled samples from healthy
individuals.29 Evaluation of measures of the range of oestrogen
metabolites in association with health-related states has been limited by
the availability of reproducible assays that target specific metabolites
and that can implemented in substantial size populations.
Our conclusion that E2 and oestrone metabolites were not acting
as potent antioxidants is contingent on the integrity of the F2a-
isoprostanes to serve as informative markers of oxidative stress. F2a-
isoprostanes, compounds produced by the free radical-induced
peroxidation of arachidonic acid,30,31 have been characterized as
superior markers of the in vivo oxidative stress response.15,32–34
Furthermore, elevated levels of F2a-isoprostanes are associated with
behaviours or conditions thought to include oxidative stress such as
smoking,35,36 alcohol consumption,17 hypercholesterolaemia,37,38
diabetes,39 liver disease,40 breast cancer41 and atherosclerotic
lesions.42 Indeed, we showed that F2a-isoprostanes values were more
than doubled in women who smoked. Additionally, F2a-isoprostanes
levels were also correlated with HDL-C in pre- and postmenopausal
women who did not smoke and with LDL in postmenopausal
women who smoked (data not shown).
To better understand the relationship between oestrogen and
F2a-isoprostanes, we adjusted for or stratified by factors that had
previously been identified as generating variation in F2a-isoprostane
concentrations. In some,7,8 but not all,9,10 studies of postmenopausal
women, oestrogen therapy acted like an antioxidant by diminishing
the level of circulating oxidized LDL. However, responses to HT may
have been inconsistently observed because preparations included
progestin products as well as oestrogens. It has been reported that
progesterone opposes the antioxidant actions of oestrogen on
plasma LDL oxidation in primates.33
Health-related and lifestyle behaviours may influence oxidative
capacity.34,43 We observed little modifying effect by diet of the
association of oestrogens with F2a-isoprostanes, based on intakes of
genistein, daidzein or total dietary fat. This is consistent with the
Table 3. Pearson (ρ, 95% confidence intervals) and partial Pearson correlations (ρY|X, 95% confidence intervals) between F2a-isoprostane concentrations and 
oestrogen measures, by menopause and smoking status
Premenopausal Postmenopausal Using hormones
ρ* 95% CI ρ* 95% CI ρ* 95% CI
Nonsmokers n = 778 n = 323 n = 325
Unadjusted
Oestradiol (pg/ml) 0·13 0·06–0·20 0·31 0·21–0·41 0·04 –0·07 to 0·15
2-Hydroxyoestrone (pg/ml) 0·43 0·37–0·49 0·43 0·33–0·51 0·34 0·24–0·44
16α-Hydroxyoestrone (pg/ml) 0·57 0·52–0·62 0·60 0·53–0·67 0·44 0·35–0·52
Adjusted*
Oestradiol (pg/ml) 0·08 0·00–0·15 0·20 0·08–0·31 0·02 –0·09 to 0·14
2-Hydroxyoestrone (pg/ml) 0·44 0·38–0·50 0·43 0·33–0·52 0·39 0·29–0·49
16α-Hydroxyoestrone (pg/ml) 0·52 0·47–0·57 0·59 0·51–0·66 0·46 0·36–0·54
Smokers n = 87 n = 44 n = 33
Unadjusted
Oestradiol (pg/ml) –0·007 –0·22 to 0·21 0·28 –0·03 to 0·55 0·04 –0·31 to 0·38
2-Hydroxyoestrone (pg/ml) 0·22 0·01–0·41 0·45 0·18–0·66 0·49 0·18–0·71
16α-Hydroxyoestrone (pg/ml) 0·36 0·16–0·53 0·62 0·40–0·78 0·43 0·10–0·67
Adjusted*
Oestradiol (pg/ml) 0·10 –0·15 to 0·34 0·38 –0·01 to 0·68 0·10 –0·43 to 0·45
2-Hydroxyoestrone (pg/ml) 0·28 0·04–0·49 0·39 0·03–0·66 0·55 0·16–0·79
16α-Hydroxyoestrone (pg/ml) 0·39 0·16–0·58 0·64 0·35–0·81 0·58 0·19–0·81
*ρY|X for adjusted values; adjusted for age, BMI, race group, lipids, physical activity level, alcohol, and having diabetes.
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findings of Block et al.,12 who reported a very modest association
with fruits, and none with vegetables, dairy foods, grains, meats or
total fat intake. In contrast to diet, we identified a very strong
association of oxidative stress with smoking behaviour. A greater
proportion of African-American and Caucasian women smoked,
compared to the low proportion of smokers in Chinese and Japanese
women, leading to greatly exaggerated mean F2a-isoprostane values
for African-American and Caucasian women. Although we evaluated
the role of passive smoking, we found only an association with
personal smoking behaviour. Women who reported more physical
activity had lower F2a-isoprostane concentrations. Others have
reported that endurance exercise is associated with increased plasma
F2a-isoprostanes in dogs,
44 horses45 and humans.46
This study had a number of strengths and limitations. A substan-
tial number of women were evaluated with representation from four
racial/ethnic groups. While this was a cross-sectional study, it was
nested in a longitudinal study of the menopausal transition, so that
menopausal status and HT use were definable within the context of
those longitudinal observations. Despite these strengths, the cross-
sectional design precluded our ability to establish a temporal
sequence between single-time measures of oestrogens and an F2a-
isoprostane index of oxidative stress. Study protocol dictated that
serum and urine be collected in the early follicular phase of the
menstrual cycle rather than in the later follicular phase or luteal
phase when oestrogen levels would be higher. As a result, we found
that low oestrogen levels did not suppress oxidative stress; however,
this does not necessarily preclude the possibility that higher
oestrogen levels as seen later in the menstrual cycle might suppress
oxidative stress. Initial criticism of the F2a-isoprostane measure-
ment by EIA was largely overcome by the use of affinity columns
to prepare the samples for analyses, as well as by improvement in
the assays that we applied in our procedures.47 EIA from eluted
samples correlated very well with other methods, including gas
chromatography–mass spectrometry.48,49 A major advantage of the
urinary measurement of F2a-isoprostanes was that they are not
formed by ex vivo autooxidation in urine, and levels were stable
even when urine was maintained at room temperature for as much
as 10 days.50,51 In addition, the concentration of F2a-isoprostanes
was unchanged with storage at –20°C.52,53 Values from repeated
days of urinary excretion tended to be the same with low intrasubject
CVs in persons, whether they were healthy or diseased.11,32,36,51
Little diurnal variation is observed, and therefore measurement of
F2a-isoprostanes in a single early morning sample has been
described as adequate to represent the daily isoprostane excretion
in humans.52
In summary, these data indicate major differences in F2a-
isoprostanes between smoking and nonsmoking women across
the menopause transition. However, there was no evidence that the
serum measure of early follicular phase E2 or urinary oestrone
metabolite measures were acting as antioxidants; indeed, the strong
adjusted and unadjusted positive correlations between the oestrone
metabolites and F2a-isoprostanes suggest an active metabolic
environment associated with the generation of free radicals.
This study refutes the commonly held hypothesis that levels of
endogenous E2 or its oestrone metabolites favourably modify
oxidative stress through a decrease in F2a-isoprostanes.
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